TY  - JOUR
AU  - Kostadinović, Jelena
AU  - Popadić, Višeslav
AU  - Klašnja, Slobodan
AU  - Klisić, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Andrić, Zoran
AU  - Zdravković, Marija
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4629
AB  - The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility.
AB  - Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Cardiotoxicity: Importance of biomarkers
T1  - Kardiotoksičnost: Važnost biomarkera
VL  - 73
IS  - 1
SP  - 1
EP  - 16
DO  - 10.5937/arhfarm73-40534
ER  - 

@article{
author = "Kostadinović, Jelena and Popadić, Višeslav and Klašnja, Slobodan and Klisić, Aleksandra and Kotur-Stevuljević, Jelena and Andrić, Zoran and Zdravković, Marija",
year = "2023",
abstract = "The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility., Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Cardiotoxicity: Importance of biomarkers, Kardiotoksičnost: Važnost biomarkera",
volume = "73",
number = "1",
pages = "1-16",
doi = "10.5937/arhfarm73-40534"
}

Kostadinović, J., Popadić, V., Klašnja, S., Klisić, A., Kotur-Stevuljević, J., Andrić, Z.,& Zdravković, M.. (2023). Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 1-16.
https://doi.org/10.5937/arhfarm73-40534

Kostadinović J, Popadić V, Klašnja S, Klisić A, Kotur-Stevuljević J, Andrić Z, Zdravković M. Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju. 2023;73(1):1-16.
doi:10.5937/arhfarm73-40534 .

Kostadinović, Jelena, Popadić, Višeslav, Klašnja, Slobodan, Klisić, Aleksandra, Kotur-Stevuljević, Jelena, Andrić, Zoran, Zdravković, Marija, "Cardiotoxicity: Importance of biomarkers" in Arhiv za farmaciju, 73, no. 1 (2023):1-16,
https://doi.org/10.5937/arhfarm73-40534 . .